No Increase in Acute or Late Radiation Toxicities in Patients With Ehlers-Danlos Syndrome Receiving Adjuvant Breast Radiation Therapy: A Report of Four Cases With Extended Follow-Up

Cureus. 2023 Dec 11;15(12):e50346. doi: 10.7759/cureus.50346. eCollection 2023 Dec.

Abstract

Ehlers-Danlos syndrome (EDS) consists of a heterogeneous group of congenital collagen formation disorders characterised by skin hyperextensibility, atrophic scarring, and generalized joint hypermobility. Collagen vascular disorders have been implicated in increased incidence and severity of radiation toxicities; however, there are limited reports on the safety of radiation therapy with EDS. We identified all patients with EDS who received adjuvant conventional and hypofractionated breast radiation therapy at our institution and reviewed patient, treatment, and toxicity characteristics. Four patients were identified with a median follow-up of 13.2 months. Acute toxicities were limited to grade 1 dermatitis in all four patients. No late toxicities were seen. In this report, radiation therapy to the breast with conventional and hypofractionated regimens resulted in no significant acute or late toxicity.

Keywords: breast cancer radiation; ehlers-danlos syndrome hypermobility type (eds-ht); ehlers-danlos syndromes; intensity modulated radiation therapy (imrt); radiation oncology complication; radiation therapy side effects; radiotherapy (rt); radiotherapy toxicity.

Publication types

  • Case Reports